Literature DB >> 1382025

Glucagon-like peptide-1(7-37)/(7-36)amide is a new incretin.

H C Fehmann1, R Göke, B Göke.   

Abstract

Glucagon-like peptide-1 (GLP-1) is the main product of the intestinal processing of proglucagon. It is released from the intestinal K-cells into the circulation in response to the oral ingestion of food. At the pancreatic beta cell GLP-1 is a potent insulin secretagogue in the presence of elevated glucose levels, defining glucagon-like peptide-1 as a new incretin. Its action is mediated by specific receptors coupled to the adenylate cyclase system by a stimulatory G-protein. Finally, glucagon-like peptide-1 stimulates proinsulin gene expression and it is thus involved at several levels in the regulation of insulin synthesis and secretion.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382025     DOI: 10.1016/0303-7207(92)90118-p

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  10 in total

1.  Regulation of microRNA-375 by cAMP in pancreatic β-cells.

Authors:  David M Keller; Elizabeth A Clark; Richard H Goodman
Journal:  Mol Endocrinol       Date:  2012-04-25

2.  Evidence that glucagon stimulates insulin secretion through its own receptor in rats.

Authors:  K Kawai; C Yokota; S Ohashi; Y Watanabe; K Yamashita
Journal:  Diabetologia       Date:  1995-03       Impact factor: 10.122

3.  A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation.

Authors:  Aisling M Lynch; Nupur Pathak; Varun Pathak; Finbarr P M O'Harte; Peter R Flatt; Nigel Irwin; Victor A Gault
Journal:  Diabetologia       Date:  2014-06-25       Impact factor: 10.122

4.  Glucagon-like peptide 1 and fatty acids amplify pulsatile insulin secretion from perifused rat islets.

Authors:  Barbara A Cunningham; Ann-Marie T Richard; Joseph S Dillon; Jennifer T Daley; Vildan N Civelek; Jude T Deeney; Gordon C Yaney; Barbara E Corkey; Keith Tornheim
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

5.  Glucagon-like peptide 1 immunoreactivity in gastroentero-pancreatic endocrine tumors: a light- and electron-microscopic study.

Authors:  R Eissele; R Göke; U Weichardt; H C Fehmann; R Arnold; B Göke
Journal:  Cell Tissue Res       Date:  1994-06       Impact factor: 5.249

6.  Structure and biological activity of glucagon and glucagon-like peptide from a primitive bony fish, the bowfin (Amia calva).

Authors:  J M Conlon; J H Youson; T P Mommsen
Journal:  Biochem J       Date:  1993-11-01       Impact factor: 3.857

Review 7.  Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.

Authors:  Curtis Triplitt; Eugenio Cersosimo; Ralph A DeFronzo
Journal:  Vasc Health Risk Manag       Date:  2010-09-07

8.  Ca2+ entry through reverse Na+/Ca2+ exchanger in NCI-H716, glucagon-like peptide-1 secreting cells.

Authors:  Kyung Jin Choi; Jin Wook Hwang; Se Hoon Kim; Hyung Seo Park
Journal:  Korean J Physiol Pharmacol       Date:  2022-05-01       Impact factor: 2.016

9.  Oral delivery of exenatide via microspheres prepared by cross-linking of alginate and hyaluronate.

Authors:  Baojie Zhang; Dongyang He; Yu Fan; Nan Liu; Yijun Chen
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

Review 10.  Implication of neurohormonal-coupled mechanisms of gastric emptying and pancreatic secretory function in diabetic gastroparesis.

Authors:  Bashair M Mussa; Sanjay Sood; Anthony Jm Verberne
Journal:  World J Gastroenterol       Date:  2018-09-14       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.